"New York Oncology Hematology (NYOH) is the leading provider of community-based cancer care and blood disorder services. With six convenient locations in Albany, Amsterdam, Clifton Park in Saratoga County, Hudson, and Troy, our team of 35 physicians and more than 350 cancer care specialists see more than 100,000 cancer visits a year."

During the past decade, New York Oncology Hematology conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 15 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 4 clinical trials were completed. i.e. 44.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New York Oncology Hematology" #1 sponsor was "Radiation Therapy Oncology Group" with 9 trials, followed by "NSABP Foundation Inc" with 8 trials sponsored, "Janssen Research & Development, LLC" with 7 trials sponsored, "Epimmune" with 3 trials sponsored and "Point Therapeutics" with 3 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New York Oncology Hematology" #1 collaborator was "National Cancer Institute (NCI)" with 19 trials as a collaborator, "NRG Oncology" with 9 trials as a collaborator, "Cancer and Leukemia Group B" with 2 trials as a collaborator, "North Central Cancer Treatment Group" with 2 trials as a collaborator and "SWOG Cancer Research Network" with 2 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "New York Oncology Hematology" are "Breast Cancer" (10 trials), "Lung Cancer" (4 trials), "Multiple Myeloma" (3 trials), "Prostate Cancer" (3 trials) and "Unspecified Adult Solid Tumor, Protocol Specific" (3 trials). Many other conditions were trialed in "New York Oncology Hematology" in a lesser frequency.

Most popular intervention types in "New York Oncology Hematology" are "Drug" (36 trials), "Radiation" (11 trials), "Biological" (10 trials), "Other" (7 trials) and "Diagnostic Test" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Prednisone" (3 trials), "cyclophosphamide" (3 trials), "docetaxel" (3 trials) and "EP2101" (2 trials). Other intervention names were less common.

The vast majority of trials in "New York Oncology Hematology" are 32 trials for "All" genders, 12 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are NaN active trials in "New York Oncology Hematology". undefined are not yet recruiting, 4 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 33 completed trials in New York Oncology Hematology, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in New York Oncology Hematology, 14 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".